"primary_site","protocol","principal_investigator","date_opened","date_closed","study_phase","title"
"Brain and Nervous System","I-546319","Abad, A","2021-07-08T00:00:00.000","2022-03-23T00:00:00.000","N/A","Expanded Access to SurVaxM for Treatment of Patients with Glioblastoma Who Have No Access to Other Comparable or Alternative Therapy or Have Completed Treatment on a non-Randomized Clinical Trial of SurVaxM and May Benefit from Further Treatment"
"Brain and Nervous System","I-813720","Abad, A","2021-12-29T00:00:00.000",,"II","Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)"
"Brain and Nervous System","I-475919","Abad, A","2019-12-30T00:00:00.000","2021-07-30T00:00:00.000","N/A","Tumor-related epilepsy:  A Prospective Cohort Study to Inform and Improve Future Clinical Trials"
"Colon","N-626620","Alarcon Velasco, S","2020-07-15T00:00:00.000",,"II","(S1922) A Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma"
"Bladder","I-1523721","Aly, A","2021-07-16T00:00:00.000",,"N/A","Transurethral Resection of Bladder Tumor (TURBT): Quality Assurance Database"
"Prostate","I-2018021","Aly, A","2021-10-07T00:00:00.000",,"N/A","Assessment of Sexual Function and Quality of Sex Life in Patients with Prostate Cancer and their Partners"
"Breast","I-724220","Ambrosone, C","2020-08-05T00:00:00.000",,"N/A","The New York Breast Cancer Study (NYBCS)"
"Breast","I-120807","Ambrosone, C","2007-12-26T00:00:00.000",,"N/A","The Women's Circle of Health Study"
"Pancreas","N-750320","Bain, A","2021-02-05T00:00:00.000",,"N/A","EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs"
"Other Hematopoietic","N-50517","Bambach, B","2018-03-14T00:00:00.000",,"II","(BMT CTN Protocol 1507) Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease"
"Other Hematopoietic","N-71918","Bambach, B","2018-10-11T00:00:00.000",,"III","(ACCL1633) The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)"
"Bones and Joints","IC-1840021","Bambach, B","2021-12-17T00:00:00.000",,"II","BMT CTN 1904 Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases"
,"I-64718","Bambach, B","2020-05-21T00:00:00.000","2021-01-07T00:00:00.000","I/II","Antiviral Cellular Therapy for Enhancing T-Cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES)"
"Multiple Sites; Leukemia, other","PH-271115","Bambach, B","2016-08-03T00:00:00.000","2021-06-10T00:00:00.000","III","(ACCL1333/CV185-155) A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Venous Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (T or B cell) Treated with Asparaginase"
"Lymphoid Leukemia","I-466719","Bambach, B","2020-04-21T00:00:00.000",,"II","A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative"
"Brain and Nervous System","N-1385821","Barth, M","2021-07-19T00:00:00.000",,"III","(ACNS1931) A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations"
"Brain and Nervous System","N-564119","Barth, M","2020-01-06T00:00:00.000",,"III","(ACNS1831) A Phase 3 Randomized Study of Selumetinib (IND # 77782) Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)"
"Brain and Nervous System","N-632820","Barth, M","2020-02-26T00:00:00.000",,"III","(ACNS1833) A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)"
"Non-Hodgkin's Lymphoma","NCG-288416","Barth, M","2017-02-16T00:00:00.000","2021-07-30T00:00:00.000","II","(COG ANHL12P1) A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC# 749005, Commercially Labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND# 117117"
"Leukemia, other","I-62318","Barth, M","2019-02-08T00:00:00.000",,"N/A","Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome"
"Other Hematopoietic","P-522219","Barth, M","2020-06-23T00:00:00.000",,"II","Acute GVHD Suppression using Costimulation Blockade to Expand Non-malignant Transplant (ASCENT)"
"Unknown Sites","I-1507721","Besharat Shafiei, S","2021-07-15T00:00:00.000",,"N/A","Analysis of physical ergonomic risk factors in human-surgical robot shared environment"
"Multiple Sites","I-1720121","Besharat Shafiei, S","2021-10-27T00:00:00.000",,"N/A","Real-time evaluation of severity of perceived pain in patients with cancer by using fNIRs, and investigation of pain relief utilizing virtual reality technologies"
"Breast","I-60217","Bonaccio, E","2018-10-18T00:00:00.000",,"N/A","Photoacoustic Imaging of Human Breast"
"Lung","I-781020","Bouchard, E","2020-11-30T00:00:00.000","2021-12-17T00:00:00.000","N/A","The Roswell AIR (Awareness, Information and Resources for Lung Cancer Screening) Program: A Community-Partnered Lung Cancer Screening Intervention"
"Multiple Sites","I-1946021","Bouchard, E","2021-10-29T00:00:00.000",,"N/A","Mindfulness Meditation"
"Unknown Sites","I-77618","Bouchard, E","2019-01-03T00:00:00.000","2021-01-05T00:00:00.000","N/A","A novel parenting skills intervention to improve medication adherence in pediatric cancer"
"Unknown Sites","I-75818","Bouchard, E","2018-12-20T00:00:00.000","2021-02-05T00:00:00.000","N/A","Enhancing infrastructure for Native American and Rural Cancer Control Research Capacity at Roswell Park Comprehensive Cancer Center"
"Unknown Sites","I-288716","Bouchard, E","2017-06-08T00:00:00.000",,"N/A","The Influence of Social Network Size, Composition and Function on Psychological Outcomes of Pediatric Cancer Caregiving: Relationships across Time and around Periods of Distress"
"Leukemia, other","I-1832021","Bouchard, E","2021-09-01T00:00:00.000",,"N/A","Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Studies 1 and 2"
"Unknown Sites","I-589019","Bouchard, E","2020-05-14T00:00:00.000",,"N/A","Examining Exposure and Adaptation to Stressors Within Patient-Caregiver Dyads and Relationships with Markers of Immune Suppression (Internal Title: Care Well)"
"Esophagus","I-57817","Buas, M","2018-01-18T00:00:00.000",,"N/A","The Roswell Park Barrett's and Esophageal Adenocarcinoma Registry (RP-BEAR)"
"Colon","I-74018","Case, A","2019-06-26T00:00:00.000","2021-11-18T00:00:00.000","II","Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center"
"Prostate","N-79118","Chatta, G","2019-02-19T00:00:00.000","2021-10-19T00:00:00.000","III","(S1802) Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer"
"Multiple Sites; Bladder","I-69518","Chatta, G","2019-04-10T00:00:00.000",,"II","(CITN-14) Randomized Phase II study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma"
"Prostate","I-63418","Chatta, G","2019-06-07T00:00:00.000",,"I/II","Phase Ib/II Study of Enzalutamide with Venetoclax (ABT-199) in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC)"
"Prostate","I-287816","Chatta, G","2017-04-03T00:00:00.000",,"I/II","Phase IB/II Study of Enzalutamide with Ribociclib in Patients with Metastatic Castrate Resistant, Chemotherapy Na√Øve Prostate Cancer that retains RB Expression"
"Prostate","I-72118","Chatta, G","2019-01-03T00:00:00.000",,"N/A","Nutrition and Exercise Interventions to Reduce Androgen Deprivation Therapy-induced Obese Frailty in Survivors of Advanced Prostate Cancer"
"Prostate","I-77318","Chatta, G","2019-11-29T00:00:00.000",,"II","Randomized Phase 2 Study: Neoadjuvant conditioning of prostate cancer tumor microenvironment using a novel chemokine-modulating regimen"
,"P-79718","Chatta, G","2020-02-14T00:00:00.000","2021-11-17T00:00:00.000","III","A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible"
"Prostate","P-637520","Chatta, G","2021-09-30T00:00:00.000",,"I/II","A Phase 1/2 Study of REGN5678 (anti-PSMAxCD28) with Cemiplimab (anti-PD-1) in Patients with Metastatic Castration-resistant Prostate Cancer (R5678-ONC-1879)"
"Prostate","I-648620","Chatta, G","2020-05-08T00:00:00.000","2021-02-19T00:00:00.000","N/A","A cross sectional study of insulin resistance and cognitive function scores in patients with prostate cancer on androgen deprivation therapy (ADT)."
"Prostate","I-43017","Chatta, G","2018-02-12T00:00:00.000","2021-06-09T00:00:00.000","N/A","IRONMAN: International Registry for Men with Advanced Prostate Cancer"
"Other Hematopoietic","I-734920","Chen, G","2021-06-15T00:00:00.000",,"II","Acalabrutinib for chronic graft versus host disease"
"Other Hematopoietic","I-905720","Chen, G","2021-06-28T00:00:00.000",,"II","Randomized, placebo-controlled, phase II trial examining ustekinumab for prevention of graft vs. host disease after allogeneic hematopoietic cell transplantation"
"Myeloid and Monocytic Leukemia","P-31916","Chen, G","2017-07-24T00:00:00.000","2021-09-20T00:00:00.000","III","A Multicenter Pivotal Phase 3 study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects with Active, Relapsed, or Refractory Acute Myeloid Leukemia"
"Other Hematopoietic","P-650420","Chen, G","2021-04-09T00:00:00.000",,"III","Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant"
,"P-81618","Chen, G","2019-12-20T00:00:00.000","2022-02-03T00:00:00.000","I/II","(EQ001-aGVHD-001) A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects with Newly Diagnosed Acute Graft Versus Host Disease"
"Multiple","P-463719","Chen, G","2021-02-24T00:00:00.000","2022-02-25T00:00:00.000","I","A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF EFMARODOCOKIN ALFA IN COMBINATION WITH STANDARD OF CARE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION"
"Multiple","P-459819","Chen, G","2020-07-28T00:00:00.000","2021-04-20T00:00:00.000","III","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation"
"Other Hematopoietic","I-735120","Chen, G","2021-02-17T00:00:00.000",,"N/A","RG1006823: Predicting the Quality of Response to Specific Treatments (PQRST): Chronic GVHD Cohort"
"Other Hematopoietic","I-590019","Chen, G","2020-08-27T00:00:00.000",,"N/A","Close Assessment and Testing for Chronic GVHD (The CATCH Study)"
"Unknown Sites","I-207511","Chen, G","2013-02-04T00:00:00.000","2021-01-28T00:00:00.000","N/A","A Pilot Study Evaluating NFAT, NFkB and, ERK 1/2 Nuclear Translocation as a Predictive Marker for Acute Graft-versus-Host Disease"
"Unknown Sites","I-270115","Chen, G","2016-04-04T00:00:00.000",,"N/A","A Preliminary Study to Determine the Effect of Donor and Recipient Vaccinations on Clinical and Laboratory Outcomes after Autologous and Allogeneic Hematopoietic Cell Transplant"
"Other Hematopoietic","I-53817","Chen, G","2018-05-01T00:00:00.000",,"N/A","The effect of extra-physiologic oxygen shock / stress (EPHOSS) on human hematopoietic stem cell viability and multi-potency"
"Lung","NCG-263614","Chen, H","2016-04-21T00:00:00.000",,"III","(E4512 )A randomized  Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein"
"Lung","N-1039720","Chen, H","2021-02-25T00:00:00.000",,"III","EA5182: Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer NSCLC)"
"Lung","N-1527721","Chen, H","2021-07-19T00:00:00.000",,"II","S1900E, A PHASE II STUDY OF SOTORASIB (AMG 510) IN PARTICIPANTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)"
"Lung","P-50817","Chen, H","2019-12-02T00:00:00.000","2021-02-01T00:00:00.000","III","RESILIENT:  A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE¬Æ) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy"
"Lung","N-19-04259","Chen, H","2019-05-08T00:00:00.000",,"II/III","(LUNGMAP) A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LungMAP Screening Study)"
"Unknown Sites","I-254114","Chodon, T","2014-06-11T00:00:00.000","2021-03-04T00:00:00.000","N/A","Cell Banking and Distribution of Leftover Human Biospecimens in the cGMP TCPF for Research Purposes"
"Melanoma, Skin","I-278415","Chowdhry, V","2017-02-07T00:00:00.000",,"I/II","(12-100) Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas"
"Lip, Oral Cavity and Pharynx; Larynx","P-549719","Dai, T","2021-09-21T00:00:00.000","2021-12-06T00:00:00.000","I","M19-894: A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma"
"Multiple Sites","P-721020","Dai, T","2021-02-19T00:00:00.000",,"I","CI-8993-101 Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients with Advanced Solid Tumor Malignancies"
"Unknown Sites","I-80418","Dean, G","2019-07-02T00:00:00.000",,"N/A","Efficacy of Nurse-Delivered Brief Behavioral Treatment to Self-Manage Insomnia in Cancer Survivors"
,"I-70818","Demmy, T","2020-07-16T00:00:00.000",,"I/II","Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable Sarcoma Pulmonary Metastases"
"Lung","I-649220","Demmy, T","2021-06-18T00:00:00.000",,"N/A","Registry Trial of Active Surveillance for Multifocal Ground Glass Opacities (GGOs)"
"Lung","NCG-263714","Dy, G","2015-01-13T00:00:00.000","2021-01-21T00:00:00.000","III","(A081105) Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)"
"Lung","NCG-263814","Dy, G","2015-01-13T00:00:00.000",,"III","(A151216) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)"
"Lung; Lip, Oral Cavity and Pharynx","I-286816","Dy, G","2016-12-22T00:00:00.000",,"I/II","A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination with the Anti-PD1 Therapy in Patients with Advanced NSCLC or Squamous Head and Neck Cancer"
"Lung","I-281616","Dy, G","2017-06-29T00:00:00.000","2022-02-08T00:00:00.000","I/II","A Phase I/II Open-label Study of Nimotuzumab in Combination with Nivolumab
in Patients with Advanced Non-small Cell Lung Cancer or Squamous Head and Neck
Cancer"
"Lung","I-691720","Dy, G","2021-07-02T00:00:00.000",,"II","A Phase II Trial of Lamivudine in Combination with Chemoimmunotherapy in Patients with Extensive Stage SCLC"
"Lung","I-82319","Dy, G","2020-02-13T00:00:00.000",,"II","Randomized Phase II Study of Pembrolizumab 200mg Every 12We eks Versus Every 3 Weeks in NSCLC with Clinical Benefit to Pembrolizumab Monotherapy: Multicenter International Study"
"Multiple Sites","P-70918","Dy, G","2019-01-31T00:00:00.000","2022-03-01T00:00:00.000","I","AMG 510 20170543 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors with KRAS p.G12C  Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation  (CodeBreak 100)."
"Lung","P-1195721","Dy, G","2021-11-24T00:00:00.000",,"II","A PHASE 2 STUDY OF BA3011 ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHO HAD PRIOR DISEASE PROGRESSION ON A PD-1/L1, EGFR, OR ALK INHIBITOR"
"Lung","P-1059120","Dy, G","2021-05-26T00:00:00.000",,"I/II","MasterKey-01: A Phase 1/2, Open-Label, Two-Part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients with Advanced Solid Malignancies"
"Lung","P-835120","Dy, G","2021-06-22T00:00:00.000",,"I/II","A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 in Patients with Advanced Cancers Associated with Expression of Delta-Like Canonical Notch Ligand 3 (DLL3) Who Have Failed Standard Available Therapy"
"Multiple Sites","P-73318","Dy, G","2019-05-30T00:00:00.000",,"I","A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)"
"Multiple","P-82519","Dy, G","2019-10-08T00:00:00.000","2021-07-27T00:00:00.000","I","An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI5395 in Combination with Durvalumab in Subjects with Select Advanced Solid Tumors"
"Lung","P-499719","Dy, G","2021-07-08T00:00:00.000",,"II","Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, nonsquamous, non small-cell lung cancer (NSQ NSCLC) patients with CEACAM5-positive tumors, previously treated with platinum-based chemotherapy and an immune checkpoint inhibitor"
"Lung","P-61618","Dy, G","2018-10-19T00:00:00.000",,"II","A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)"
"Lung","I-945720","Dy, G","2021-01-08T00:00:00.000",,"N/A","Patients  Preferences for Adjuvant Osimertinib or Atezolizumab for NSCLC after Complete Surgical Resection."
"Breast","I-60517","Edge, S","2019-02-06T00:00:00.000","2021-09-23T00:00:00.000","N/A","Breast Cancer Pathways Impact on Patient Shared Decision Making and Experience in Academic and Community Practice"
"Colon","I-63518","Erwin, D","2019-05-01T00:00:00.000","2021-04-09T00:00:00.000","N/A","Increasing access and developing predictors for colorectal cancer screening for minority and Medicaid clients"
"Multiple","P-40016","Fabiano, A","2017-04-07T00:00:00.000",,"N/A","Vigilant Observation of Gliadel Wafer Implant (VIGILANT) Registry: A multicenter, observational registry to collect information on the safety and effectiveness of Gliadel Wafer (Carmustine Implant) used in usual medical practice"
"Unknown Sites","I-1574221","Felicione, N","2021-08-31T00:00:00.000",,"N/A","Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Cigarette Smokers Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study]"
"Brain and Nervous System","I-286416","Fenstermaker, R","2016-09-15T00:00:00.000",,"N/A","Non-Therapeutic Exploratory Study of Serum Molecular Markers in Brain Tumor Patients Undergoing Surgical Resection of their Tumors"
"Pancreas","IC-1171721","Fountzilas, C","2021-06-04T00:00:00.000",,"I/II","(10366) A Phase I/2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the treatment of Locally Advanced Pancreatic Adenocarcinoma"
"Pancreas","N-1191721","Fountzilas, C","2021-07-22T00:00:00.000",,"II","(S2001) Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations"
"Colon; Rectum","I-444019","Fountzilas, C","2019-11-08T00:00:00.000",,"II","A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO)"
"Multiple","I-650120","Fountzilas, C","2021-05-28T00:00:00.000",,"I","A Phase I Study of Trifluridine/ Tipiracil plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers"
"Pancreas; Colon","I-797920","Fountzilas, C","2021-12-30T00:00:00.000",,"N/A","Perioperative Analysis of Binimetinib and Palbociclib in RAS-driven tumors"
"Colon","I-49617","Fountzilas, C","2018-05-15T00:00:00.000","2021-10-01T00:00:00.000","II","(ACCRU-GI-1617) MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer"
"Pancreas","P-1688021","Fountzilas, C","2021-11-22T00:00:00.000",,"I/II","A PHASE 1b/2 RANDOMIZED STUDY OF AVB-S6-500 PLUS NAB-PACLITAXEL AND GEMCITABINE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA"
"Multiple","P-569719","Fountzilas, C","2021-07-26T00:00:00.000",,"I","9801-CL-0101 A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors"
"Stomach","P-58917","Fountzilas, C","2019-01-23T00:00:00.000","2022-02-23T00:00:00.000","III","(ISN 8951-CL-0301) A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362)  Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"
"Multiple Sites","P-75218","Fountzilas, C","2019-11-05T00:00:00.000",,"II","(8951-CL-5201): A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma"
"Pancreas","P-535719","Fountzilas, C","2020-11-25T00:00:00.000","2021-08-13T00:00:00.000","III","(CORT125134-553) A Phase 3 Study of Relacorilant in Combination with      Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)"
"Multiple Sites","P-697120","Fountzilas, C","2021-03-02T00:00:00.000",,"I/II","DF6002-001: A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a monotherapy and in combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications"
"Stomach; Esophagus","P-71618","Fountzilas, C","2020-08-11T00:00:00.000",,"II","(HCRN ESO17-325) A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients with Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) high Metastatic
Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma"
"Multiple Sites","P-73818","Fountzilas, C","2019-02-12T00:00:00.000","2021-02-11T00:00:00.000","I","A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors  (POD1UM-102)"
"Pancreas","P-646520","Fountzilas, C","2021-02-08T00:00:00.000","2021-07-26T00:00:00.000","III","D-US-60010-001 An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas"
"Multiple Sites","P-539719","Fountzilas, C","2020-09-30T00:00:00.000",,"Early Phase I","A phase 1, open-label, multiple-ascending dose study to investigate the safety,
pharmacokinetics, pharmacodynamics, and preliminary efficacy of KD033 in subjects with metastatic or locally advanced solid tumors"
"Multiple Sites","PH-278115","Fountzilas, C","2016-06-07T00:00:00.000","2021-02-08T00:00:00.000","I","A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects with Advanced Malignancies"
"Pancreas; Multiple Sites","P-71518","Fountzilas, C","2019-03-06T00:00:00.000","2021-06-30T00:00:00.000","I/II","A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma"
"Multiple Sites","P-46317","Fountzilas, C","2019-01-04T00:00:00.000","2021-12-31T00:00:00.000","II","PUMA-NER-5201, An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations"
,"P-776020","Fountzilas, C","2021-03-11T00:00:00.000","2021-10-07T00:00:00.000","N/A","Screening protocol to detect HER2 alterations required for enrollment on clinical research protocols of tucatinib"
"Corpus Uteri","N-517719","Frederick, P","2020-01-23T00:00:00.000",,"III","NRG-GY018, A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer"
"Breast","N-1764921","Fung-Kee-Fung, S","2021-09-16T00:00:00.000",,"III","NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE &#8804; 18 BREAST CANCER"
"Breast","N-79418","Fung-Kee-Fung, S","2018-11-07T00:00:00.000",,"II","(S1706) A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer"
"Breast","I-621720","Fung-Kee-Fung, S","2020-06-02T00:00:00.000",,"N/A","Pilot study of the surveillance and analysis of radiation dermatitis among breast cancer patients using deep machine learning"
"Breast","I-61918","Gandhi, S","2019-04-24T00:00:00.000",,"II","A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer"
"Breast","I-68018","Gandhi, S","2019-02-12T00:00:00.000","2022-02-15T00:00:00.000","II","A randomized phase II study to evaluate efficacy of TDM1with or without Palbociclib in the treatment of patients with metastatic HER2 positive breast cancer"
"Melanoma, Skin","I-53217","Gandhi, S","2018-01-31T00:00:00.000",,"I/II","A Phase Ib/II Study of Propranolol with Fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma"
"Breast","I-73718","Gandhi, S","2019-12-06T00:00:00.000",,"I","Phase I Clinical Trial Assessing the Combination of Chemokine Modulation with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer"
"Multiple Sites","P-78818","Gandhi, S","2019-07-03T00:00:00.000",,"I","(ALKS 4230-001) A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)"
"Multiple Sites","PH-285316","Gandhi, S","2016-11-21T00:00:00.000","2021-08-04T00:00:00.000","I","A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors- ARTISTRY -1"
"Multiple Sites","P-74818","Gandhi, S","2019-08-01T00:00:00.000","2022-01-21T00:00:00.000","I","A Phase 1 Study with Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Eribulin ORA (HM30181A + Eribulin) in Subjects with Solid Tumors (ATX-ERB-001)"
"Breast","IC-1243721","Gandhi, S","2021-07-29T00:00:00.000",,"N/A","Detection by circulating RNA with OPtimized machine LEarning Technology for Breast Cancer: DROPLET-BC Study"
"Kidney","N-1095820","George, S","2021-11-22T00:00:00.000",,"III","(S1931) Phase III Trial of Immunotherapy-Based Drug Combination Therapy With Or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE TRIAL)"
"Bladder","I-40216","George, S","2018-12-20T00:00:00.000","2021-01-07T00:00:00.000","II","Phase II trial of Concurrent Nivolumab in UroThelial Bladder Cancer with Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]"
"Kidney","I-191711","George, S","2012-10-05T00:00:00.000",,"I/II","A Phase I/ II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients"
"Kidney","P-39016","George, S","2017-09-14T00:00:00.000","2021-09-10T00:00:00.000","II","A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)"
"Kidney","P-42016","George, S","2017-11-29T00:00:00.000","2022-02-21T00:00:00.000","III","A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse"
"Bladder; Kidney","P-615220","George, S","2021-04-26T00:00:00.000",,"II","Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab"
"Kidney","P-844420","George, S","2021-06-29T00:00:00.000",,"III","A Phase 3, Open-label, Randomized, Non-Inferiority Trial of Subcutaneous (SC) versus Intravenous (IV) Nivolumab in Advanced, or Metastatic Clear-Cell Renal Cell Carcinoma (RCC) Who Have Received Prior Anti-Angiogenic Therapy"
"Bladder; Kidney","P-70518","George, S","2019-05-20T00:00:00.000","2021-12-15T00:00:00.000","II","A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti-PD-a/ PD-L1 Based Immunotherapy"
"Bladder","P-834720","George, S","2021-12-23T00:00:00.000",,"III","A Randomized Open-Label Phase III Study of Sacituzumab Govitecan versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer"
"Kidney","P-845720","George, S","2021-10-27T00:00:00.000",,"III","An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety
of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)"
"Kidney","P-864820","George, S","2021-07-08T00:00:00.000","2021-11-19T00:00:00.000","II","Phase 2 Study of MK-6482 in Participants with Advanced Renal Cell Carcinoma"
"Multiple","P-57417","George, S","2018-04-17T00:00:00.000",,"I","SGN22E-002 A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer"
"Kidney","P-777920","George, S","2021-09-30T00:00:00.000",,"I","A Phase 1 Study of SRF388 in Patients with Advanced Solid tumors"
"Other Hematopoietic; Hodgkin's Lymphoma","I-503719","Ghione, P","2021-05-28T00:00:00.000",,"II","A Phase II Study of Pembrolizumab and Entinostat in Patients with Relapsed and Refractory Lymphomas (17-073)"
"Multiple","P-35616","Ghione, P","2017-12-22T00:00:00.000","2021-01-08T00:00:00.000","I/II","(ASTX660-01) Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas"
"Non-Hodgkin's Lymphoma","I-1279721","Ghione, P","2021-07-02T00:00:00.000",,"N/A","Prospective, observational, non-interventional feasibility study of Minimal Residual Disease assessment with CAncer Personalized Profiling by deep sequencing in patients with newly diagnosed peripheral T cell lymphoma."
"Unknown Sites","I-891720","Glaser, K","2021-02-19T00:00:00.000",,"N/A","Influence of Yoga on Cancer-Related Stress in Cancer Survivors"
,"I-629420","Glaser, K","2020-04-17T00:00:00.000","2022-02-03T00:00:00.000","N/A","Assessing Barriers to Care and Task Force Development to Increase Breast Health Equity"
"Unknown Sites","I-63018","Glaser, K","2018-05-23T00:00:00.000",,"N/A","Understanding health behaviors and perceptions of cancer in non-English speaking populations"
"Lung","I-70618","Goniewicz, M","2018-08-30T00:00:00.000",,"N/A","Changes in respiratory symptoms and inflammation markers among e-cigarette users during spontaneous ""switching"" between flavors (CRoFT_3.1)"
"Other Female Genital","I-59317","Goniewicz, M","2018-08-21T00:00:00.000",,"N/A","Electronic Cigarette Use During Pregnancy"
"Unknown Sites","P-522019","Goniewicz, M","2019-11-15T00:00:00.000",,"N/A","International E-cigarette Study - Youth"
"Lung","P-76718","Goniewicz, M","2018-11-27T00:00:00.000",,"N/A","CONNECT (Clinical Outcomes of Nationwide, Naturalistic E-Cig Trial)"
"Other Urinary","N-1353721","Gopalakrishnan, D","2021-08-30T00:00:00.000",,"III","(A031901) DURATION OF IMMUNE CHECKPOINT THERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA: A RANDOMIZED PHASE 3 NON-NFERIORITY TRIAL (IMAGINE)"
"Soft Tissue","N-979720","Grand'Maison, A","2021-05-07T00:00:00.000",,"II","(A091902) A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Na√Øve, and Nivolumab and Carbozantinb in Taxane Pretreated Subjects With Angiosarcoma"
"Soft Tissue","I-56317","Grand'Maison, A","2018-07-30T00:00:00.000","2021-07-15T00:00:00.000","II","A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma"
"Leukemia, other","P-756220","Green, S","2021-02-15T00:00:00.000",,"I","A Phase 1b Study of ABBV-744 Alone or in Combination with Ruxolitinib or Navitoclax in Subjects with Myelofibrosis"
"Leukemia, other","P-622220","Green, S","2020-12-17T00:00:00.000",,"I","A Phase I, Open-label, Dose escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis"
"Myeloid and Monocytic Leukemia; Other Hematopoietic","P-19-04239","Green, S","2020-03-17T00:00:00.000","2021-06-24T00:00:00.000","II","A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment"
"Myeloid and Monocytic Leukemia","I-67118","Griffiths, E","2019-12-02T00:00:00.000","2021-02-19T00:00:00.000","II","A Phase II Study of Intensive Salvage Therapy Followed by Enasidenib for Patients with AML Harboring Mutations in IDH2 who have Failed or been Refractory to Frontline Therapy"
"Myeloid and Monocytic Leukemia","I-54017","Griffiths, E","2017-10-17T00:00:00.000",,"IV","Evaluation of antibody response to high-dose seasonal influenza vaccination in patients with myeloid malignancy receiving chemotherapy"
"Myeloid and Monocytic Leukemia; Other Hematopoietic","P-543719","Griffiths, E","2020-09-16T00:00:00.000",,"I/II","A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)"
"Lymphoid Leukemia","P-654120","Griffiths, E","2021-04-16T00:00:00.000","2021-11-17T00:00:00.000","I","A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)"
"Prostate","P-78418","Griffiths, E","2019-11-25T00:00:00.000",,"I/II","A randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)"
"Myeloid and Monocytic Leukemia","P-810020","Griffiths, E","2021-04-02T00:00:00.000",,"I","A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia"
"Leukemia, other","P-1263721","Griffiths, E","2021-10-25T00:00:00.000",,"II/III","A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis"
"Other Respiratory and Intrathoracic Organs; Unknown Sites","N-734020","Griffiths, E","2020-11-05T00:00:00.000","2021-09-22T00:00:00.000","N/A","NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study"
,"I-1151721","Griffiths, E","2021-03-12T00:00:00.000",,"N/A","Evaluation of Safety and Immune Responses to COVID-19 Vaccination in Patients with Cancer"
"Multiple","I-449719","Griffiths, E","2020-02-10T00:00:00.000",,"N/A","Evaluation of patients with hematopoietic disorders and their family members for known or suspected inherited predisposition."
"Leukemia, other","PH-213112","Griffiths, E","2013-04-22T00:00:00.000",,"N/A","Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry"
"Unknown Sites","I-67818","Grimmer, J","2019-03-21T00:00:00.000",,"N/A","Routine nurse-led follow up in a chronic cancer pain management clinic for patients started on adjuvant neuropathic pain medications: Are patient outcomes improved?"
"Soft Tissue","N-2224021","Gupta, A","2021-12-16T00:00:00.000",,"III","(ARST2031) A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)"
,"I-875720","Gupta, A","2021-03-08T00:00:00.000",,"N/A","(MCC-20320) Blood based biomarkers for minimal residual disease detection in pediatric sarcomas"
"Bladder","I-573720","Guru, K","2020-08-04T00:00:00.000",,"IV","Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection after Robot Assisted Radical Cystectomy"
"Prostate","I-822320","Guru, K","2020-11-30T00:00:00.000",,"N/A","Investigating the correlation between the Brain and Pelvic Floor Muscle Activity of Patients Undergoing Robot-Assisted radical Prostatectomy"
"Bladder","P-48517","Guru, K","2018-03-30T00:00:00.000",,"II","CA-ALT-803-01-16 QUILT-3.032:  A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer"
"Prostate","I-198211","Guru, K","2011-09-13T00:00:00.000",,"N/A","Prostate Cancer Database: Clinical Parameters"
"Unknown Sites","I-241913","Guru, K","2013-07-17T00:00:00.000",,"N/A","Evaluation and Assessment of Cognition, Perception, and Motor Skills during Robot Assisted Surgery"
"Unknown Sites","I-244113","Guru, K","2014-07-01T00:00:00.000",,"N/A","Observational Study to Identify Patterns in Communication and Team Interaction in the Operating Room"
"Multiple","I-461719","Guru, K","2019-10-23T00:00:00.000",,"N/A","Understanding How Visual Imagery Can Impact Training in Robot Assisted Surgery"
"Bladder","I-53017","Guru, K","2018-03-01T00:00:00.000",,"N/A","Spatial Analysis of Bladder Cancer in Western New York"
"Prostate","I-77718","Guru, K","2019-01-09T00:00:00.000",,"N/A","Impact of a National Comprehensive Cancer Network Compliant Multidisciplinary Consortium on Treatment Decisions in Patients with Localized Prostate Cancer"
"Bladder","I-258714","Guru, K","2015-10-01T00:00:00.000",,"N/A","Assessment of Circulating Tumor Cells in Blood and Irrigation Fluid During Robot-Assisted Radical Cystectomy"
"Kidney","I-53605","Guru, K","2005-04-14T00:00:00.000",,"N/A","Kidney Cancer Database and Use of Existing Tissue Resources 1983-Present"
,"I-73418","Hahn, T","2021-07-13T00:00:00.000",,"N/A","INSPIRE: A Multicenter Randomized Controlled Trial integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantation"
"Other Hematopoietic","IC-1052320","Hahn, T","2021-09-09T00:00:00.000",,"N/A","A Prospective Analysis of Biochemical Markers for Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy in Adults"
,"I-810620","Haring, R","2021-01-08T00:00:00.000",,"N/A","A Novel Sugar-Sweetened Beverage Reduction Intervention for Native American Men"
"Lymphoid Leukemia","N-563819","Hernandez, F","2020-08-12T00:00:00.000",,"II/III","A051701Randomized phase II/III study of venetoclax (ABT 199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double-expressing lymphomas"
"Other Hematopoietic","N-83919","Hernandez, F","2019-04-22T00:00:00.000",,"III","(A041702) A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 65 Years of Age)With Chronic Lymphocytic Leukemia"
"Multiple","N-19-04141","Hernandez, F","2019-06-21T00:00:00.000","2021-05-04T00:00:00.000","III","EA9161: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)"
"Lymphoid Leukemia","N-478019","Hernandez, F","2020-02-06T00:00:00.000","2021-09-22T00:00:00.000","II","S1608) Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma"
"Non-Hodgkin's Lymphoma","I-240813","Hernandez, F","2014-04-17T00:00:00.000","2021-02-19T00:00:00.000","I","Phase I/Ib Study of Carfilzomib plus Rituximab plus Ifosfamide plus Carboplatin plus Etoposide (C-R-ICE) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)"
"Multiple","P-439919","Hernandez, F","2020-08-12T00:00:00.000",,"N/A","Long-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T Cells"
"Non-Hodgkin's Lymphoma","P-915720","Hernandez, F","2021-05-27T00:00:00.000","2021-09-23T00:00:00.000","I/II","A Multicenter, Phase 1/2 Study of Selinexor in Combination with Backbone Treatments or Novel Therapies in Patients with Relapsed or Refractory (RR) Diffuse Large B-cell Lymphoma (DLBCL)"
"Non-Hodgkin's Lymphoma; Lymphoid Leukemia","P-82619","Hernandez, F","2019-10-23T00:00:00.000","2021-12-16T00:00:00.000","I/II","A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)"
"Non-Hodgkin's Lymphoma","P-809820","Hernandez, F","2021-11-16T00:00:00.000",,"III","A Phase 3, multicenter, randomized, double-blind, placebo- controlled trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high- risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)"
"Non-Hodgkin's Lymphoma; Other Hematopoietic","P-465719","Hernandez, F","2020-06-03T00:00:00.000","2021-02-11T00:00:00.000","I","A Phase 1 Study of OT-82 in Patients with Relapsed or Refractory Non-Hodgkin s Lymphoma"
"Non-Hodgkin's Lymphoma","P-56917","Hernandez, F","2019-02-01T00:00:00.000","2021-09-02T00:00:00.000","I","Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects with Relapsed and/or Refractory B Cell Lymphoma"
"Non-Hodgkin's Lymphoma; Leukemia, other","CIC-01-16","Hernandez, F","2001-08-24T00:00:00.000",,"N/A","Collection of Blood from Healthy Donors and Patients with Lymphoma and Leukemia to Study the Immunological Activity of Peripheral Blood Mononuclear cells (PBMC) and Human Serum"
"Non-Hodgkin's Lymphoma","I-38216","Hernandez, F","2017-05-01T00:00:00.000","2021-01-12T00:00:00.000","N/A","Biomarkers of response to biological agents and/or chemotherapy agents in relapsed/refractory diffuse large B-cell lymphoma patients"
"Non-Hodgkin's Lymphoma","I-42804","Hernandez, F","2005-02-11T00:00:00.000",,"N/A","Evaluation of Changes in The Structure of CD20 and Downstream Signaling in Patients with Rituximab Resistant/Refractory B-Cell Lymphomas and Leukemia"
"Lip, Oral Cavity and Pharynx","I-281415","Hicks, W","2016-04-05T00:00:00.000",,"N/A","Clinical and Pathological Prognosticators of Incidence, Progression and Survival in Head and Neck Cancers and Indications and Outcomes of Cancer-Related Plastic/Reconstructive Surgery"
"Multiple Myeloma","I-47217","Hillengass, J","2018-06-25T00:00:00.000",,"II","Phase II Study of Targeting CD28 in Multiple Myeloma with Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy"
"Multiple Myeloma","I-247913","Hillengass, J","2016-03-09T00:00:00.000",,"I","A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in  patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy"
"Multiple Myeloma","I-657720","Hillengass, J","2020-08-24T00:00:00.000","2021-06-28T00:00:00.000","N/A","Pilot Study of Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients with Multiple Myeloma"
"Multiple Myeloma","I-70118","Hillengass, J","2019-09-05T00:00:00.000",,"N/A","Feasibility of Strength Training and Impact on Pain and Quality of Life in Patients with Multiple Myeloma"
"Multiple Myeloma; Other Hematopoietic","P-432519","Hillengass, J","2019-12-10T00:00:00.000",,"I","A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY OF CC-99712, A BCMA ANTIBODYDRUG CONJUGATE, IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA"
"Multiple Myeloma","P-821720","Hillengass, J","2021-10-26T00:00:00.000",,"I/II","A PHASE 1/2 MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CC-92480 MONOTHERAPY AND IN COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (CC-92480-MM-00)"
"Multiple Myeloma","P-555719","Hillengass, J","2021-01-22T00:00:00.000",,"I/II","A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory  Multiple Myeloma (HPN217-3001)"
"Multiple Myeloma","P-550219","Hillengass, J","2020-06-11T00:00:00.000",,"II","A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma"
"Multiple Myeloma","P-58817","Hillengass, J","2018-06-25T00:00:00.000","2021-02-04T00:00:00.000","I","An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma"
"Multiple Myeloma","P-864020","Hillengass, J","2021-06-30T00:00:00.000","2021-12-30T00:00:00.000","II","MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY"
"Multiple Myeloma","I-478219","Hillengass, J","2020-03-11T00:00:00.000","2021-07-30T00:00:00.000","IV","Correlation between 24-Hour Urine Protein and of Spot Urine Protein-to-Creatinine Ratio in Multiple Myeloma (Spot Study)"
"Multiple Myeloma","P-846420","Hillengass, J","2021-02-22T00:00:00.000",,"N/A","Health Related Quality of Life in Multiple Myeloma"
"Multiple Sites","I-66418","Hillengass, J","2019-03-04T00:00:00.000",,"N/A","Characterization of Focal Lesions in Monoclonal Plasma Cell Disorders over the Course of the Disease"
"Unknown Sites","I-37216","Hiscock, M","2017-01-24T00:00:00.000",,"N/A","Moral Distress in Nurses providing direct patient care on inpatient oncology units and outpatient clinics"
"Multiple","I-40916","Ho, C","2017-12-07T00:00:00.000",,"II","A PHASE II TRIAL OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION UTILIZING MOBILIZED PERIPHERAL BLOOD STEM CELLS."
"Multiple Sites","I-44417","Ho, C","2017-08-03T00:00:00.000",,"I/II","A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation with Post Transplant Cyclophosphamide as Graft versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation"
"Multiple Myeloma","P-552019","Ho, C","2020-09-22T00:00:00.000","2021-10-27T00:00:00.000","II","A PHASE I STUDY OF HUMAN PLACENTAL HEMATOPOIETIC
STEM CELL DERIVED NATURAL KILLER CELLS (CYNK-001)
IN MULTIPLE MYELOMA PATIENTS FOLLOWING
AUTOLOGOUS STEM CELL TRANSPLANT IN THE FRONTLINE SETTING (CYNK-001-MM-002)"
,"I-673720","Hong, C","2020-07-06T00:00:00.000",,"N/A","Women's Health after Breast Cancer II Study: Understanding How Adrenergic Stress Influences Breast Cancer Prognosis"
,"I-839720","Hutson, A","2021-01-12T00:00:00.000",,"N/A","Administrative Supplement to Cancer Moonshot Coordinating Center (CC) to Support the Mechanisms of Cancer Drug Resistance and Sensitivity Network (DRSN)"
,"I-806620","Hyland, A","2021-01-06T00:00:00.000",,"N/A","Educating Smokers about Lung Cancer Screening using Tobacco Quitlines"
"Lung","P-1431721","Ivanick, N","2021-12-07T00:00:00.000",,"N/A","Collection of human-derived, healthy and disease-specific biological samples for the development and control of laboratory assays, procedures and general research"
"Lung","I-62305","Ivanick, N","2005-07-26T00:00:00.000",,"N/A","Lung Bronchoscopy Research Samples & Database"
"Lung","P-1261721","Ivanick, N","2021-12-24T00:00:00.000",,"N/A","Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung"
"Lung","I-279415","Ivanick, N","2020-02-04T00:00:00.000",,"II","Endobronchial Ultrasound Transbronchial Needle guided Interstitial Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer and Advanced Cancers Obstructing the Airway -Phase I/IIa Study"
"Pancreas","N-74618","Iyer, R","2018-10-31T00:00:00.000",,"III","(A021602) RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON PRIOR THERAPY"
"Multiple","N-83019","Iyer, R","2019-04-30T00:00:00.000","2021-02-15T00:00:00.000","III","(SWOG S1815) A Phase III Randomized Trial of Gemcitabine, Cisplatin, and NAB-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers"
"Multiple","N-641920","Iyer, R","2020-08-12T00:00:00.000",,"II","EA2187,  A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma"
,"P-973720","Iyer, R","2021-10-05T00:00:00.000",,"II","(HCRN GI19-405) A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)"
"Multiple","I-64518","Iyer, R","2019-06-17T00:00:00.000",,"II","Phase 2 Single-Arm Study of Nanoliposomal Irinotecan with Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin"
"Liver","I-35316","Iyer, R","2017-09-13T00:00:00.000",,"I/II","A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)"
"Multiple","I-79518","Iyer, R","2019-06-13T00:00:00.000",,"I","A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs)"
"Liver","P-521819","Iyer, R","2020-09-04T00:00:00.000",,"I/II","A Phase 1b/2, Open-Label, Study of Tivozanib in Combination with
Durvalumab in Subjects with  Advanced Hepatocellular Carcinoma"
"Liver","P-83819","Iyer, R","2020-01-10T00:00:00.000","2021-02-01T00:00:00.000","II","( LX1606.1-207-BTC ) A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO¬Æ (Telotristat Ethyl) plus First-line Chemotherapy in Patients with Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)"
"Multiple","I-70218","Iyer, R","2018-11-05T00:00:00.000",,"N/A","Roswell Park Neuroendocrine Tumor Biobank"
"Soft Tissue","N-65118","Kane, J","2019-02-27T00:00:00.000","2021-07-13T00:00:00.000","I","(NRG-DT001) A Phase IB Trial Of Neoadjuvant AMG 232 (KRT-232)Concurrent With Preoperative Radiotherapy In Wild-Type P53 Soft Tissue Sarcoma (STS)"
,"I-255314","Kane, J","2014-06-24T00:00:00.000",,"N/A","Tissue Procurement Protocol for the Developmental Therapeutics Clinic, NCI"
,"N-825920","Kelly, K","2021-02-22T00:00:00.000",,"I/II","A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma"
"Hodgkin's Lymphoma","N-529719","Kelly, K","2019-12-20T00:00:00.000",,"III","(S1826) A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA (NCT03907488)"
"Lymphoid Leukemia","I-48717","Kelly, K","2017-08-29T00:00:00.000",,"N/A","Implementing a Low Glycemic Diet in Children and Adolescents Undergoing Treatment for Acute Lymphoblastic Leukemia"
"Lymphoid Leukemia","I-43517","Kelly, K","2017-09-01T00:00:00.000",,"III","DFCI ALL Consortium 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents"
,"I-841820","Kelly, K","2021-04-02T00:00:00.000",,"N/A","(SPARK Cluster RCT) Symptom Screening Linked to Care Pathways for Children with Cancer: a Cluster Randomized Trial"
"Hodgkin's Lymphoma","P-489819","Kelly, K","2020-03-03T00:00:00.000",,"II","An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)"
"Lung","P-824220","Keppel, A","2021-01-28T00:00:00.000",,"N/A","GAPPS: Guidance And Preparation for Patients with Non-Small Cell Lung Cancer: Pilot Study"
"Unknown Sites","I-270915","Kisailus, A","2015-12-28T00:00:00.000",,"N/A","The Impact of Summer Research Experience Programs on Preparing and Encouraging High School, Undergraduate and Medical Students for Advanced Education and Careers in Cancer Research"
"Prostate","N-1347921","Kuettel, M","2021-05-27T00:00:00.000",,"III","NRG-GU009: PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)
*Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation"
"Prostate","N-509819","Kuettel, M","2019-12-16T00:00:00.000",,"II","NRG-GU007,RANDOMIZED PHASE II TRIAL OF NIRAPARIB WITH STANDARD COMBINATION RADIOTHERAPY AND ANDROGEN DEPRIVATION THERAPY (ADT) IN HIGH RISK PROSTATE CANCER (WITH INITIAL PHASE I) (NADIR*)
*Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I)"
"Esophagus","I-283516","Kukar, M","2016-12-30T00:00:00.000",,"II","Double-arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II)"
"Unknown Sites","I-268815","Lau, J","2015-06-05T00:00:00.000",,"N/A","Platelets in Extrinsic Glycosylation"
"Other Female Genital","N-1660021","Lele, S","2021-09-28T00:00:00.000",,"II","NRG-GY023: A RANDOMIZED PHASE II TRIAL OF TRIPLET THERAPY (A PD-L1 INHIBITOR DURVALUMAB (MEDI4736) IN COMBINATION WITH OLAPARIB AND CEDIRANIB) COMPARED TO OLAPARIB AND CEDIRANIB OR DURVALUMAB (MEDI4736) AND CEDIRANIB OR STANDARD OF CARE CHEMOTHERAPY IN WOMEN WITH PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL OR FALLOPIAN CANCER WHO HAVE RECEIVED PRIOR BEVACIZUMAB (NCT#04739800)"
"Other Female Genital; Ovary","N-55817","Lele, S","2018-03-08T00:00:00.000",,"III","(NRG-GY006) A Randomized phase III trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer"
"Ovary","N-71218","Lele, S","2018-12-07T00:00:00.000","2021-10-15T00:00:00.000","II/III","A RANDOMIZED, PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN, CTEP-SUPPLIED BEVACIZUMAB AND CTEP-SUPPLIED ATEZOLIZUMAB VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEPSUPPLIED
BEVACIZUMAB IN PLATINUM RESISTANT OVARIAN CANCER"
"Cervix Uteri; Other Female Genital","N-80018","Lele, S","2019-04-08T00:00:00.000","2021-11-23T00:00:00.000","I","(NRG-GY017) Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer"
"Cervix Uteri","N-830320","Lele, S","2021-03-01T00:00:00.000",,"N/A","NRG-GY022, Assessment of carboplatin clearance predictors: a PK study on NCI-sponsored clinical trials or standard of care treatments using carboplatin (NCT# 03997370)"
"Breast","N-1274321","Levine, E","2021-05-27T00:00:00.000",,"III","(A011801) The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib"
"Multiple","N-465919","Levine, E","2019-10-07T00:00:00.000","2021-11-24T00:00:00.000","II","(A031702) Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors"
"Bladder","N-58417","Levine, E","2018-03-01T00:00:00.000","2021-08-25T00:00:00.000","III","(A031501) Phase III Randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma (AMBASSADOR) versus observation"
"Bladder","N-78918","Levine, E","2019-03-28T00:00:00.000","2021-06-01T00:00:00.000","II","(A031701) A PHASE II STUDY OF GEMCITABINE PLUS CISPLATIN CHEMOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS"
"Breast","N-935821","Levine, E",,,"III","(A221702)ARM: Axillary Reverse Mapping-A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping"
"Breast","NCG-245113","Levine, E","2014-04-08T00:00:00.000",,"III","(A011202) A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 NI) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy"
"Multiple Sites","NCG-275215","Levine, E","2016-06-01T00:00:00.000",,"N/A","(EAY 131 Master Protocol) Molecular Analysis for Therapy Choice (MATCH)"
"Other Male Genital","NCG-275515","Levine, E","2016-05-31T00:00:00.000","2021-09-30T00:00:00.000","III","(A031102) A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Pacilitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors"
"Brain and Nervous System","N-76518","Levine, E","2019-07-09T00:00:00.000",,"III","(COG #AGCT1532) Phase 3 Accelerated BEP Trial:A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours"
"Multiple Myeloma","N-2104021","Levine, E",,,"III","Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation"
"Breast","N-646320","Levine, E","2020-06-25T00:00:00.000",,"N/A","EA1181 (CompassHER2 pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response"
"Breast","NCG-275315","Levine, E","2016-09-09T00:00:00.000","2021-03-30T00:00:00.000","III","(EA1131) A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy"
"Breast","N-431719","Levine, E","2019-07-08T00:00:00.000",,"III","NRG-BR004,""A Randomized, Double-Blind, Phase III Trial of 
Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line 
HER2-Positive Metastatic Breast Cancer,"" (NCT03199885)"
"Breast","N-50117","Levine, E","2017-07-27T00:00:00.000",,"II","NRG-BR005: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery"
"Brain and Nervous System","N-949721","Levine, E",,,"II/III","NRG-BN007:A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma"
"Breast","NCG-275415","Levine, E","2016-03-03T00:00:00.000",,"III","A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer"
"Other Urinary","N-1497721","Levine, E","2021-07-15T00:00:00.000",,"III","S1937,A PHASE III RANDOMIZED TRIAL OF ERIBULIN (NSC #707389) WITH OR WITHOUT GEMCITABINE VERSUS STANDARD OF CARE (PHYSICIAN S CHOICE) FOR TREATMENT OF METASTATIC UROTHELIAL CARCINOMA REFRACTORY TO, OR INELIGIBLE FOR, ANTI PD1/PDL1 THERAPY"
"Breast","N-2106021","Levine, E",,,"II","A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases"
"Breast","P-622020","Levine, E","2021-02-03T00:00:00.000",,"II","PrE0113:A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 Avelumab and Paclitaxel BRACELET-1 Study"
"Breast","P-48217","Levine, E","2018-07-23T00:00:00.000",,"N/A","MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)"
"Multiple","P-81418","Lipinski, L","2019-03-12T00:00:00.000",,"N/A","3D Prediction of Patient-specific Response using Ex vivo Interrogation of Live Cells from Tumors"
"Lung; Unknown Sites","I-476019","Malik, N","2019-11-07T00:00:00.000",,"N/A","Initial Development and Validation of a Hemoptysis Evaluation Tool"
"Multiple","N-429819","McCarthy, P","2019-09-11T00:00:00.000",,"N/A","(BMTCTN 1702) Clinical Transplant - Related Long-term Outcomes of ALthernative Donor ALlogenic Transplantation ( CTRL-ALT-D)"
"Multiple Sites","I-258514","McCarthy, P","2017-06-30T00:00:00.000","2021-03-04T00:00:00.000","I/II","A Phase I/IIa Study of TGF√ü Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients with Advanced Malignancies"
,"I-78618","McCarthy, P","2019-12-19T00:00:00.000","2022-01-11T00:00:00.000","II","A Phase II Multicenter, Single Arm, Open-Label Trial to Evaluate the Efficacy and Safety of Denosumab in Treatment of Post-Allogenic Hematopoietic Stem Cell Transplant Bone Loss"
"Non-Hodgkin's Lymphoma","P-867120","McCarthy, P","2021-03-09T00:00:00.000",,"I","A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies"
,"P-869720","McCarthy, P","2021-07-27T00:00:00.000",,"N/A","Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release (bb2121-EAP-001)"
"Multiple Myeloma","P-612020","McCarthy, P","2020-11-11T00:00:00.000",,"I","A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CC-98633, BCMA-TARGETED NEX-T CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA"
"Other Hematopoietic","P-707720","McCarthy, P","2021-05-13T00:00:00.000",,"N/A","EXPANDED ACCESS PROTOCOL (EAP) FOR PATIENTS RECEIVING LISOCABTAGENE MARALEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE (JCAR017-EAP-001)"
"Other Hematopoietic","P-545719","McCarthy, P","2020-09-10T00:00:00.000","2021-04-28T00:00:00.000","I/II","A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)"
"Other Hematopoietic","P-917720","McCarthy, P","2021-07-13T00:00:00.000","2021-12-17T00:00:00.000","II","A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination with Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies"
"Non-Hodgkin's Lymphoma; Lymphoid Leukemia","P-80318","McCarthy, P","2019-02-27T00:00:00.000",,"N/A","Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release"
"Other Hematopoietic","I-577719","McCarthy, P","2020-08-05T00:00:00.000","2021-12-20T00:00:00.000","N/A","BMTCTN 1704, Composite Health Assessment Risk Model for Older Adults:
Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to PredictNon-Relapse Mortality After Allogeneic Transplant (CHARM)"
"Leukemia, other","NCG-202611","McCarthy, P","2011-10-19T00:00:00.000",,"N/A","(CIBMTR 10-CBA) A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications"
"Multiple Sites","P-54517","McCarthy, P","2018-06-06T00:00:00.000","2021-02-24T00:00:00.000","N/A","(ADP-0000-001) A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies"
"Other Hematopoietic","NCG-00403","McCarthy, P","2003-03-28T00:00:00.000",,"N/A","Center for International Blood and Marrow Transplant Research Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries"
"Multiple Sites","I-226412","McCarthy, P","2014-02-14T00:00:00.000","2021-03-29T00:00:00.000","N/A","NY-ESO-1 Expression in Patients with Solid Tumors"
"Other Hematopoietic","I-57217","McCarthy, P","2019-04-18T00:00:00.000",,"Early Phase I","A Pilot Study generating a biorepository to correlate Bio Markers and outcomes of Cellular Therapy Patients"
"Lip, Oral Cavity and Pharynx","N-842020","McSpadden, R","2021-03-09T00:00:00.000",,"III","NRG HN006:RANDOMIZED PHASE II/III TRIAL OF SENTINEL LYMPH NODE BIOPSY VERSUS ELECTIVE NECK DISSECTION FOR EARLY-STAGE ORAL CAVITY CANCER"
"Prostate","P-42116","Mohler, J","2017-08-10T00:00:00.000","2022-03-15T00:00:00.000","III","A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer"
"Multiple Sites","I-78218","Mohler, J","2019-06-06T00:00:00.000","2021-07-31T00:00:00.000","N/A","(2018-01) Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors"
"Breast; Stomach","I-79218","Moon, W","2019-02-07T00:00:00.000",,"N/A","Comparing Unilateral and Bilateral Deep Inferior Epigastric Perforators (DIEP) Flaps for unilateral breast reconstruction"
"Lung; Multiple Sites","I-681920","Morrison, C","2020-05-20T00:00:00.000","2021-03-11T00:00:00.000","N/A","T-cell and B-cell receptor repertoire diversity as biomarkers of progression in individuals with positive testing for COVID-19: A Western New York Immunogenomic Biomarker Study"
"Ovary","EPR-01103","Moysich, K","2003-05-20T00:00:00.000",,"N/A","Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer"
"Colon","N-59217","Mukherjee, S","2018-04-26T00:00:00.000",,"III","(A021502) Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch"
"Anus","N-1001720","Mukherjee, S","2021-02-12T00:00:00.000",,"III","EA2176  A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Na√Øve Metastatic Anal Cancer Patients"
"Anus","N-68518","Mukherjee, S","2018-12-22T00:00:00.000","2021-09-10T00:00:00.000","II","(EA2165) A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer"
"Anus","I-76618","Mukherjee, S","2018-12-13T00:00:00.000","2022-03-25T00:00:00.000","II","(NCI 9673)  Part B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (Amendment)"
"Stomach; Esophagus","I-533819","Mukherjee, S","2021-01-08T00:00:00.000",,"II","Phase II study of short course FOLFOX chemotherapy with either Nivolumab or Nivolumab + Radiation in the first line treatment of metastatic or unresectable gastroesophageal cancers (BMS Protocol CA209-76L)."
"Stomach; Esophagus","I-443819","Mukherjee, S","2019-12-10T00:00:00.000",,"II","Use of Trifluridine/tipiracil (TAS-102) and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and gastroesophageal junction (GEJ) adenocarcinoma"
"Multiple","P-457819","Mukherjee, S","2020-06-04T00:00:00.000",,"I","A Phase I/IIa, Multicenter, Open-Label Study of Nous-209 Genetic 
Vaccine for the Treatment of Microsatellite Unstable Solid Tumors"
"Prostate","I-285716","Nastiuk, K","2017-09-21T00:00:00.000",,"N/A","Alteration of Serum Cytokines During ADT in Treatment-Naive Prostate Cancer Patients"
"Multiple","I-517819","Nwogu, C","2020-06-05T00:00:00.000",,"N/A","Technology Enhanced Multidisciplinary Oncology Care"
"Unknown Sites","I-80518","O'Connor, R","2019-09-19T00:00:00.000",,"N/A","Consumer Assessment of Tobacco Flavor and Odor"
,"I-757820","O'Connor, R","2020-12-04T00:00:00.000",,"N/A","Effects of filter ventilation and ventilation information on product use behaviors in cigarette smokers (COMET 2 3.1)"
"Unknown Sites","I-471719","O'Connor, R","2019-10-07T00:00:00.000",,"N/A","Nicotine Vapor Specific Sensory Measurement"
"Unknown Sites","I-72518","O'Connor, R","2019-08-29T00:00:00.000",,"N/A","Methods for characterizing flavor impact on user behavior and perceptions"
"Unknown Sites","I-68718","O'Connor, R","2018-10-23T00:00:00.000",,"N/A","Effects of filter ventilation on sensory response, smoking topography, and inhalation (COMET 2 2.1)"
"Unknown Sites","I-1389821","O'Connor, R","2021-05-17T00:00:00.000",,"N/A","Web based surveys to assess perceptions and intention to use emerging heated tobacco products."
"Unknown Sites","I-285916","O'Connor, R","2016-06-21T00:00:00.000","2021-04-05T00:00:00.000","Early Phase I","Pilot Studies of Functional Near Infrared Spectroscopy in Behavioral and Communications Research"
,"I-567719","O'Connor, R","2020-07-20T00:00:00.000",,"N/A","New York State Health Behavior and Policy Survey"
"Breast","N-30716","O'Connor, T","2017-01-26T00:00:00.000","2021-02-15T00:00:00.000","III","A011401; Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer"
"Breast","I-778720","O'Connor, T","2020-12-22T00:00:00.000",,"II","A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination with 
Endocrine Therapy in Patients Age 70 and Older with Hormone Receptor Positive 
Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition"
"Breast","I-32816","O'Connor, T","2017-10-06T00:00:00.000",,"N/A","Exercise to Improve Health and Quality-of-life in Breast Cancer Survivors:  A Feasibility Pilot Trial"
"Breast","I-67518","O'Connor, T","2018-11-09T00:00:00.000",,"N/A","Exercise and Nutrition Intervention in Older Breast Cancer Survivors"
"Breast","P-575719","O'Connor, T","2020-10-06T00:00:00.000","2021-08-26T00:00:00.000","II","An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2-Breast Cancer with an ESR1 Mutation"
"Breast","P-887720","O'Connor, T","2021-08-23T00:00:00.000","2022-01-21T00:00:00.000","N/A","EndoPredict¬Æ Extended Endocrine Trial (EXET): A prospective registry to evaluate the impact of the EndoPredict¬Æ test on extended endocrine treatment decisions and patient outcomes"
"Multiple","P-479819","Odunsi, K","2020-07-17T00:00:00.000","2021-02-25T00:00:00.000","Early Phase I","ADP-0055-001: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND EFFICACY OF ADP-A2M4CD8 IN HLA-A2+ SUBJECTS WITH MAGE-A4 POSITIVE TUMORS"
,"P-63318","Odunsi, K","2020-02-14T00:00:00.000","2021-01-28T00:00:00.000","I","A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer"
"Other Female Genital; Ovary","I-45717","Odunsi, K","2018-04-12T00:00:00.000","2022-02-04T00:00:00.000","N/A","TISSUE AND DATA ACQUISITION ACTIVITY FOR THE STUDY OF GYNECOLOGIC DISEASE"
"Lung","I-208611","Pokharel, S","2012-04-24T00:00:00.000",,"N/A","European Thoracic Oncology Platform (ETOP) Lungscape Master Protocol"
"Lung","N-642120","Prasad, D","2020-08-05T00:00:00.000",,"III","(S1827)MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)"
"Myeloid and Monocytic Leukemia","I-501719","Przespolewski, A","2020-05-15T00:00:00.000",,"II","A Phase II Study of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia"
"Myeloid and Monocytic Leukemia","I-694020","Przespolewski, A","2021-03-26T00:00:00.000",,"N/A","Treatment practices and outcomes of adults with therapy-related acute myeloid leukemia (AML) and AML with myelodysplasia related changes"
"Brain and Nervous System; Melanoma, Skin","N-913820","Puzanov, I","2021-02-23T00:00:00.000",,"II","(S2000) A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases"
"Melanoma, Skin","N-1021720","Puzanov, I","2021-02-22T00:00:00.000",,"II","EA6192: A Phase II Study of Biomarker Driven Early Discontinuation of anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)"
"Multiple Sites","I-32316","Puzanov, I","2016-11-15T00:00:00.000","2021-01-05T00:00:00.000","I","(CITN-12) Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm"
"Other Skin; Lymphoid Leukemia","I-56717","Puzanov, I","2018-08-17T00:00:00.000","2021-01-22T00:00:00.000","II","NCI 10057: A Phase II Study of talimogene laherparepvec (T-VEC) Followed by talimogene laherparepvec (T-VEC) + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors"
"Multiple Sites","N-45117","Puzanov, I","2017-06-30T00:00:00.000","2022-03-09T00:00:00.000","I/II","(S1609) DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors"
"Melanoma, Skin","N-84019","Puzanov, I","2019-06-24T00:00:00.000",,"II","(S1801) A PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT Pembrolizumab (MK-3475) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA"
"Multiple","I-291016","Puzanov, I","2018-01-22T00:00:00.000","2021-04-30T00:00:00.000","I/II","A phase 1/2 Study of in situ vaccination with tremelimumab and IV durvalumab (MEDI4736) plus the Toll-like receptor agonist PolyICLC in Subjects with Advanced, Measurable, Biopsy-accessible Cancers"
"Other Skin","I-50417","Puzanov, I","2018-11-05T00:00:00.000","2021-08-06T00:00:00.000","III","A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 antibody) in Merkel Cell Carcinoma Patients with Lymph Node Metastases (Adjuvant Avelumab in MCC (ADAM) Trial"
"Pancreas; Multiple Sites","P-73618","Puzanov, I","2019-02-07T00:00:00.000",,"I","ADCT-301-103: A Phase 1b, Open-Label, Dose-Escalation and DoseExpansion Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine
(ADCT-301) as Monotherapy or in Combination in Patients With
Selected Advanced Solid Tumors"
"Multiple Sites","P-719720","Puzanov, I","2021-01-22T00:00:00.000",,"I","D7880C00001 An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination with Durvalumab in Participants with Select Advanced/Metastatic Solid Tumors"
"Non-Hodgkin's Lymphoma; Multiple Sites","P-66118","Puzanov, I","2019-01-17T00:00:00.000","2021-08-04T00:00:00.000","I","CPI-006-001 A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD 73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS"
,"P-67418","Puzanov, I","2020-09-29T00:00:00.000","2021-09-03T00:00:00.000","I","FUSION FPX-01-01 A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumours"
"Multiple","P-83519","Puzanov, I","2020-08-13T00:00:00.000","2021-05-07T00:00:00.000","I","A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH BEMPEGALDESLEUKIN (NKTR-214) AND IN COMBINATION WITH BEMPEGALDESLEUKIN PLUS NIVOLUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES"
"Melanoma, Skin","I-441819","Puzanov, I","2020-03-13T00:00:00.000","2021-09-03T00:00:00.000","I/II","A phase 1b/2a, open label study to evaluate anti-tumor efficacy and safety of rhIL-7-hyFc (NT-I7) in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 na√Øve or relapsed/refractory high-risk skin cancers"
"Melanoma, Skin","P-47916","Puzanov, I","2018-04-06T00:00:00.000",,"II","The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment"
"Multiple","P-553719","Puzanov, I","2020-06-29T00:00:00.000",,"Early Phase I","ONCR-177-101 A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination with PD-1 Blockade in Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors"
"Multiple Sites","P-667720","Puzanov, I","2020-04-01T00:00:00.000","2020-07-02T00:00:00.000","II/III","An adaptive Phase 2/3, randomized, double -blind, placeb0-controlled study assessing efficacy and safety of Sarilumab for hospitalized patients with COVID-19"
"Unknown Sites","I-60717","Quinn, T","2018-08-28T00:00:00.000",,"IV","General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial:  Pragmatic Randomized Trial of Propofol vs Volatile Inhalational Anesthesia"
"Unknown Sites","I-475819","Quisenberry, A","2019-12-31T00:00:00.000",,"N/A","Pharmacokinetics, subjective effects, and abuse liability of nicotine salt-based vaping products with tobacco or unflavored e-liquids [SALTVAPE Study]"
"Unknown Sites","I-75418","Quisenberry, A","2018-10-01T00:00:00.000",,"N/A","Flavored Tobacco Product Regulation: Behavioral Economic Demand, Visual Attention, and Flavored Tobacco Product Availability"
"Unknown Sites","I-477719","Quisenberry, A","2019-09-12T00:00:00.000",,"N/A","Determining the appeal and abuse liability of heated tobacco products: qualitative and behavioral economic evaluation of the role of flavor"
,"I-806120","Quisenberry, A","2021-02-17T00:00:00.000",,"N/A","Substitutability of Cigarettes for Salt- and Free-Base Ends Devices in Young Adult Ends Users in a Menthol Flavor Ban"
,"I-650320","Quisenberry, A","2020-08-26T00:00:00.000",,"N/A","Evaluation of tobacco product litter policy within an Experimental Tobacco Marketplace"
"Unknown Sites","I-694620","Quisenberry, A","2020-09-16T00:00:00.000",,"N/A","A sugar-sweetened beverage (SSB) marketplace for diverse adults"
"Lung","I-511919","Reid, M","2021-03-19T00:00:00.000",,"Early Phase I","A Phase 0 Study of CIMAvax-EGF vaccine in Patients Who Are At High Risk for Lung Cancer and Lung Cancer Survivors at Risk for Recurrence"
"Lung","I-96706","Reid, M","2007-02-07T00:00:00.000","2022-01-05T00:00:00.000","N/A","The Stacey Scott  Lung Cancer Registry"
"Unknown Sites","I-2132221","Riebandt, G","2021-12-16T00:00:00.000",,"N/A","Identifying Best Practices in Oncology Biosimilar Implementation"
"Unknown Sites","I-1998021","Rodriguez, E","2021-11-13T00:00:00.000",,"N/A","Implementation of Evidence-Based Strategies to Optimize HPV Vaccination in Rural Primary Care Settings"
"Lymphoid Leukemia","N-58317","Rokitka, D","2018-01-31T00:00:00.000",,"N/A","(ALTE1631) A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Cancer"
"Multiple Sites","N-925420","Rokitka, D","2021-01-14T00:00:00.000",,"III","(ALTE2031) StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors"
"Other Respiratory and Intrathoracic Organs","NCG-287516","Rokitka, D","2016-09-21T00:00:00.000","2021-01-25T00:00:00.000","II","(COG ALTE1621) Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial"
"Unknown Sites","I-69418","Rokitka, D","2019-01-18T00:00:00.000",,"N/A","Aromatherapy: An Integrative Option for Symptom Management in Cancer Care"
"Brain and Nervous System","N-56017","Rokitka, D","2018-01-17T00:00:00.000","2021-09-20T00:00:00.000","N/A","ALTE 15N2 LEAHRN (Late Effects After High-Risk Neuroblastoma) Study"
"Other Male Genital","N-80818","Rokitka, D","2019-01-30T00:00:00.000",,"N/A","(ALTE16C1) Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma"
"Kidney","POG-9442","Rokitka, D","1995-05-22T00:00:00.000","2021-01-30T00:00:00.000","N/A","(CHOB 291) National Wilms Tumor # 5:  Late Effects Study"
"Unknown Sites","I-34216","Rokitka, D","2017-03-16T00:00:00.000","2021-01-25T00:00:00.000","N/A","2016 National AYA Patient and Survivor Survey"
"Unknown Sites","I-186310","Rokitka, D","2011-05-20T00:00:00.000",,"N/A","Examining Quality of Life Among Long-Term Survivors of Childhood Cancer"
"Unknown Sites","NCG-246313","Rokitka, D","2013-11-14T00:00:00.000",,"N/A","(COG ALTE11C2) Health Effects After Anthracycline and Radiation Therapy (HEART):  Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy"
"Unknown Sites","I-1968021","Schneller, L","2021-11-03T00:00:00.000",,"N/A","Focus Groups to Evaluate Consumer Reactions to Tobacco 21 and Contemporaneous Effects"
"Multiple Sites","I-659920","Segal, B","2020-09-04T00:00:00.000",,"I/II","Phase 1/2A Study of Rintatolimod and IFN alpha Regimen in Cancer Patients with Mild or Moderate COVID-19 Infection"
"Lung","I-65718","Sheffer, C","2018-09-04T00:00:00.000",,"N/A","Enhancing Relapse Prevention with rTMS: Dose-Response Parameters for Smoking Cessation"
"Breast","I-72218","Sheffer, C","2019-01-16T00:00:00.000","2021-10-01T00:00:00.000","N/A","Enhancing a home-based walking intervention among breast cancer survivors with rTMS: Feasibility and limited efficacy testing"
"Lung","I-82819","Sheffer, C","2019-05-03T00:00:00.000",,"N/A","Promising methods to decrease delay discounting and reduce relapse to smoking"
,"I-455719","Sheffer, C","2019-12-18T00:00:00.000",,"N/A","Cancer Research Education Curriculum Development Project"
"Unknown Sites","I-64918","Sheffer, C","2018-06-21T00:00:00.000",,"N/A","Evaluation of Roswell Park Cessation Services"
"Multiple","I-290616","Sherrow, C","2016-10-12T00:00:00.000",,"N/A","Conventional vs iPad-based Education for Gastrointestinal Cancer Patients Undergoing Chemotherapy: A Non-Interventional Study"
"Lip, Oral Cavity and Pharynx; Esophagus","N-505719","Singh, A","2019-11-01T00:00:00.000",,"II/III","EA3161: A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA"
"Multiple","N-66918","Singh, A","2019-06-10T00:00:00.000",,"II","EA3163:Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)"
"Lip, Oral Cavity and Pharynx","N-61217","Singh, A","2019-04-04T00:00:00.000",,"II/III","(NRG-HN004) Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin"
"Multiple","N-798320","Singh, A","2021-01-28T00:00:00.000",,"III","PROTOCOL RTOG 1216: RANDOMIZED PHASE II/III TRIAL OF ADJUVANT RADIATION THERAPY WITH CISPLATIN, DOCETAXEL-CETUXIMAB, OR CISPLATIN-ATEZOLIZUMAB IN PATHOLOGIC HIGH-RISK SQUAMOUS CELL CANCER OF THE HEAD AND NECK (NCT 01810913)"
"Multiple","I-56617","Singh, A","2018-06-18T00:00:00.000",,"N/A","A Pilot Study of Photoacoustic Imaging (PAI)"
"Lip, Oral Cavity and Pharynx","I-48917","Singh, A","2018-04-02T00:00:00.000",,"Early Phase I","A Pilot Study of Photoacoustic Imaging (PAI) in H&N Cancer Patients"
,"I-79318","Singh, A","2021-05-06T00:00:00.000",,"N/A","Survivor Warming to AlteR Mood (S-WARM)"
"Esophagus","I-630420","Singh, A","2021-04-01T00:00:00.000",,"II","Propranolol with Standard Chemoradiation for Esophageal Adenocarcinoma - A Combined Single Arm and Randomized Cohort Phase II Study"
"Lung","I-1307721","Singh, A","2021-12-16T00:00:00.000",,"N/A","A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer"
"Lung","I-50717","Singh, A","2017-12-18T00:00:00.000",,"Early Phase I","Three Pilot Studies of Stereotactic Body Radiation Therapy (SBRT) and Surgery in Non-Small Cell Lung Cancer"
"Lip, Oral Cavity and Pharynx","I-61117","Singh, A","2018-05-03T00:00:00.000","2021-03-11T00:00:00.000","II","A Randomized, Open-Label Study to Assess the Pain, Toxicity and Quality of Life Effects of Adding Venlafaxine to the Pain Management Regimen for Patients Treated with Chemoradiation for Head and Neck Cancer"
"Multiple Sites","I-81318","Singh, A","2019-11-18T00:00:00.000",,"II","A Phase 2 Randomized Study with a non-Randomized Cohort: Assessing Single-fraction SBRT versus STandard PalliativE Radiation In Patients with Metastatic Disease (ASTEROID)"
"Lung","I-81919","Singh, A","2019-11-06T00:00:00.000",,"I","A Feasibility and Toxicity Analysis of Single Fraction Stereotactic Body Radiation Therapy for Post-Operative Non-Small Cell Lung Cancer"
"Unknown Sites","I-45417","Singh, A","2017-05-23T00:00:00.000",,"N/A","Understanding the Prevalence of Malnutrition Risk Among Cancer Patients Undergoing Radiation Treatment at RPCI"
"Multiple Sites","I-60017","Skitzki, J","2019-07-01T00:00:00.000",,"I","A Single-center Phase I Dose Escalation/Response Trial to Evaluate the Safety, Tolerability, and Anti-tumor Efficacy of Intra-arterial CBL0137 for Patients with Advanced Extremity Melanoma or Sarcoma"
"Unknown Sites","I-1239721","Smith, D","2021-03-30T00:00:00.000",,"N/A","Prevalence and Perceptions of Cannabis Use among Cancer Patients"
"Prostate","I-44117","Sumlin, A","2017-08-29T00:00:00.000",,"N/A","Race and geographic differences in diagnosis with metastatic Prostate cancer and early detection"
"Prostate","I-76918","Sumlin, A","2019-01-04T00:00:00.000",,"N/A","The Impact of Financial Distress on Prostate Cancer Treatment: A Feasibility Study"
"Breast","I-63718","Takabe, K","2018-08-17T00:00:00.000","2021-05-21T00:00:00.000","N/A","Global Identification of Cancer Biology in the Tumors of Primary or Metastatic Breast Cancer"
"Myeloid and Monocytic Leukemia","N-79018","Thompson, J","2018-12-19T00:00:00.000",,"II","(S1712) A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease"
"Myeloid and Monocytic Leukemia","I-537719","Thompson, J","2020-12-03T00:00:00.000",,"II","Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation"
"Leukemia, other","P-1357721","Thompson, J","2021-06-16T00:00:00.000","2021-09-27T00:00:00.000","N/A","Expanded Access Program (EAP) for avapritinib in Patients with Advanced Systemic Mastocytosis (AdvSM)"
"Myeloid and Monocytic Leukemia","P-1567721","Thompson, J","2021-08-27T00:00:00.000","2021-12-14T00:00:00.000","N/A","Managed Access Program (MAP)* to provide access to asciminib for patients with CML in chronic phase, with or without documented T315I mutation, without comparable or satisfactory alternative therapy to treat the disease"
"Other Hematopoietic","NCG-288816","Thompson, J","2017-01-06T00:00:00.000",,"N/A","The National Myelodysplastic Syndromes (MDS) Study"
"Lymphoid Leukemia","N-588719","Torka, P","2020-06-29T00:00:00.000","2021-01-26T00:00:00.000","II","EA4181,  A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients &#8804; 70 years old with Untreated Mantle Cell Lymphoma"
"Non-Hodgkin's Lymphoma","N-1598021","Torka, P","2021-08-19T00:00:00.000",,"II/III","(S1918) A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements."
"Lymphoid Leukemia; Other Hematopoietic","I-80618","Torka, P","2020-01-28T00:00:00.000","2021-03-24T00:00:00.000","I/II","A Phase I/II Study of Carfilzomib in Combination with R-CHOP (CR CHOP) for Patients with Diffuse Large B-Cell Lymphoma"
"Non-Hodgkin's Lymphoma; Lymphoid Leukemia","I-69018","Torka, P","2019-03-08T00:00:00.000","2022-01-06T00:00:00.000","I","A Phase I Study of pevonedistat (MLN4924, TAK924) in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin lymphoma"
"Non-Hodgkin's Lymphoma","P-66518","Torka, P","2019-04-11T00:00:00.000","2021-12-17T00:00:00.000","II","A Phase II Study of Palbociclib (PD-0332991) in Combination with Ibrutinib in Patients with Previously Treated Mantle Cell Lymphoma"
"Non-Hodgkin's Lymphoma; Myeloid and Monocytic Leukemia","I-573919","Torka, P","2020-09-23T00:00:00.000",,"I","An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients with High Risk Hematologic Malignancies (VICC HEM1755)"
"Other Hematopoietic","I-657920","Torka, P","2020-06-10T00:00:00.000","2021-10-04T00:00:00.000","N/A","Evaluating the Role of Baseline Geriatric Assessment in Predicting Adherence and Outcomes in Older Patients with Lymphoid Malignancies on Oral Targeted Therapies"
"Unknown Sites","I-217912","Travers, M","2012-08-07T00:00:00.000",,"N/A","Evaluating Tobacco Product Displays in the Retail Environment"
"Unknown Sites","I-106907","Travers, M","2007-07-20T00:00:00.000",,"N/A","Evaluation of Smoker Reactions to Novel Tobacco Products"
"Non-Hodgkin's Lymphoma","N-2216221","Twist, C","2021-12-16T00:00:00.000",,"III","(ANHL1931) A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma"
"Myeloid and Monocytic Leukemia","N-2246021","Twist, C","2021-12-16T00:00:00.000",,"II","(AAML18P1) Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)"
"Brain and Nervous System","N-479919","Twist, C","2019-12-10T00:00:00.000",,"II","(COG ANBL1821) A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma"
"Multiple Sites","N-52617","Twist, C","2017-11-09T00:00:00.000",,"III","AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors"
"Multiple Sites","N-55017","Twist, C","2018-01-09T00:00:00.000",,"N/A","(APEC1621) NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)"
,"N-55017-C","Twist, C","2020-08-12T00:00:00.000","2021-05-13T00:00:00.000","II","(APEC1621C) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF TAZEMETOSTAT IN PATIENTS WITH TUMORS HARBORING ALTERATIONS IN EZH2 OR MEMBERS OF THE SWI/SNF COMPLEX"
,"N-55017-D","Twist, C","2020-03-04T00:00:00.000",,"II","(APEC1621D) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF LY3023414 IN PATIENTS WITH SOLID TUMORS"
,"N-55017-J","Twist, C","2021-09-07T00:00:00.000","2021-09-07T00:00:00.000","II","(APEC1621J) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) - PHASE 2 SUBPROTOCOL OF BVD-523FB (ULIXERTINIB) IN PATIENTS WITH TUMORS HARBORING ACTIVATING MAPK PATHWAY MUTATIONS"
"Multiple","N-55017-SC","Twist, C","2018-01-09T00:00:00.000",,"II","(APEC1621SC) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL"
"Lymphoid Leukemia","N-56517","Twist, C","2018-12-20T00:00:00.000",,"II","(AALL1621) A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)"
"Lymphoid Leukemia","N-57617","Twist, C","2018-04-04T00:00:00.000",,"III","AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones"
"Brain and Nervous System","N-58017","Twist, C","2018-01-31T00:00:00.000",,"II","ACNS1422 A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients"
"Brain and Nervous System","N-608820","Twist, C","2020-05-13T00:00:00.000",,"II","(ACNS1723) A Phase 2 Study of Dabrafenib (NCS#763760) with Trametinib (NCS# 763093) after Local Irradiation in Newly-Diagnosed BRAFv600-Mutant High-Grade Glioma (HGG) (IND#145355)"
"Lymphoid Leukemia","N-609220","Twist, C","2020-04-29T00:00:00.000",,"III","AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin(IND#:133494, NSC#:772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-InductionTherapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy"
"Brain and Nervous System","N-71718","Twist, C","2018-07-18T00:00:00.000",,"III","(ANBL1531) A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma"
"Liver","N-74918","Twist, C","2018-10-11T00:00:00.000",,"II/III","(COG AHEP1531) Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)"
"Leukemia, other","N-784720","Twist, C","2020-10-13T00:00:00.000",,"III","(AAML1831) A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations"
"Brain and Nervous System","N-83219","Twist, C","2019-06-25T00:00:00.000","2021-10-27T00:00:00.000","II","(COG ACNS1721) A Phase 2 Study of Veliparib and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High Grade Glioma (HGG) without H3K27M or BRAFV600 Mutations"
"Kidney","N-871820","Twist, C","2020-12-16T00:00:00.000",,"II","Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)"
"Soft Tissue","N-924720","Twist, C","2021-02-25T00:00:00.000",,"II","(ARST1921) A Safety, Pharmacokinetic and Efficacy Study of a gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375),in Children and Adolescents with  progressive, Surgically Unresectable Desmoid Tumors"
"Brain and Nervous System","NCG-272315","Twist, C","2015-06-19T00:00:00.000",,"III","(COG ANBL1232) Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma"
"Myeloid and Monocytic Leukemia","NCG-289616","Twist, C","2017-02-13T00:00:00.000",,"III","(COG AAML1531) Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome"
"Soft Tissue","NCG-290716","Twist, C","2018-02-08T00:00:00.000",,"III","(COG ARST1431) A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)"
"Lymphoid Leukemia; Leukemia, other","I-431919","Twist, C","2020-07-08T00:00:00.000",,"I","Phase I trial of ribociclib in combination with everolimus and dexamethasone in children and young adults with relapsed acute lymphoblastic leukemia"
"Lymphoid Leukemia","PH-286916","Twist, C","2017-09-08T00:00:00.000",,"II","INCB 18424-269 (COG AALL1521) A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia"
"Lymphoid Leukemia","P-507919","Twist, C","2020-12-17T00:00:00.000",,"II","(AALL1721) A Phase II trial of tisagenlecleucel in first-line high risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy"
"Unknown Sites","NCG-279615","Twist, C","2016-03-09T00:00:00.000",,"N/A","(COG APEC14B1) The Project:  Everychild Protocol:  A Registry, Eligibility Screening, Biology and Outcome Study"
"Brain and Nervous System","COG-ANBL00B1","Twist, C","2001-04-17T00:00:00.000",,"N/A","(CHOB 665) Neuroblastoma Biology Studies"
"Kidney","NCG-77006","Twist, C","2006-05-30T00:00:00.000",,"N/A","(COG AREN03B2/CHOB 2061) Renal Tumors Classification, Biology and Banking Study"
"Unknown Sites","I-629020","Walter, M","2020-09-16T00:00:00.000",,"N/A","A Survey to Determine Cancer Patients  Perceptions of the Difficulties Encountered When Filling Opioid Prescriptions"
"Lymphoid Leukemia","N-57017","Wang, E","2018-08-20T00:00:00.000",,"III","(A041501) A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL"
"Lymphoid Leukemia; Leukemia, other","N-2012021","Wang, E","2021-12-22T00:00:00.000",,"I/II","A Phase I/II Study of AKR1C3-Activated Prodrug Obi-3424 (Obi-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)"
"Lymphoid Leukemia","NCG-269115","Wang, E","2016-03-08T00:00:00.000","2021-08-31T00:00:00.000","II","A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone,Vincristine,Methotrexate,6 Mercaptopurine) for Pts >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Neg (Ph-) ALL and of Dasatinib (NSC 732517) , Prednisone and Blinatumomab for Pts >/= 65 Years of Age with Newly Diagnosed Ph+ ALL, Relapsed/Refractory Ph+ ALL, and Ph-Like Signature ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)"
"Lymphoid Leukemia; Myeloid and Monocytic Leukemia","I-497719","Wang, E","2021-03-18T00:00:00.000",,"I","A Phase 1 Study of ABL001 in combination with dasatinib and prednisone in patients with BCR-ABL positive (BCR-ABL+) B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML)"
"Myeloid and Monocytic Leukemia; Other Hematopoietic","I-435819","Wang, E","2020-07-23T00:00:00.000",,"I","Phase 1/1b Trial of Talazoparib and Gemtuzumab ozogamicin in Adult Patients with Relapsed and/or Refractory Acute Myeloid Leukemia"
"Leukemia, other","I-66818","Wang, E","2021-01-21T00:00:00.000","2021-12-17T00:00:00.000","I/II","A Multi-center, Open-label Phase 1b/2 Study of Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Adult Patients with Relapsed/Refractory B lineage Acute Lymphoblastic Leukemia (B-ALL)"
"Myeloid and Monocytic Leukemia","P-481719","Wang, E","2021-04-08T00:00:00.000",,"I","A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Acute Myeloid Leukemia"
"Myeloid and Monocytic Leukemia","P-52217","Wang, E","2018-09-11T00:00:00.000",,"III","(ARO-021) Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia"
"Myeloid and Monocytic Leukemia","P-53517","Wang, E","2018-11-01T00:00:00.000",,"III","(ARO-013) Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects = 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia"
"Myeloid and Monocytic Leukemia","P-567819","Wang, E","2020-08-18T00:00:00.000",,"I","A PHASE I MULTI-DOSE STUDY OF HUMAN PLACENTAL HEMATOPOIETIC STEM CELL 
DERIVED NATURAL KILLER CELLS (CYNK-001) WITH OR WITHOUT RECOMBINANT HUMAN  INTERLEUKIN-2 (RHIL-2) IN ADULTS WITH PRIMARY OR SECONDARY ACUTE MYELOID LEUKEMIA (AML) IN MORPHOLOGIC COMPLETE REMISSION WITH MINIMAL RESIDUAL DISEASE (MRD) OR RELAPSED/REFRACTORY AML"
"Myeloid and Monocytic Leukemia; Leukemia, other","P-66618","Wang, E","2019-03-01T00:00:00.000","2021-01-25T00:00:00.000","I","A Phase 1 Study of Milademetan in combination with Quizartinib in subjects with FLT3 ITD mutant Acute Myeloid Leukemia that are relapsed/refractory, or newly diagnosed and unfit for intensive chemotherapy"
"Myeloid and Monocytic Leukemia; Leukemia, other","P-50917","Wang, E","2018-05-11T00:00:00.000","2021-05-06T00:00:00.000","I","A Phase 1/2, Multicenter, Open-Label, Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation"
"Myeloid and Monocytic Leukemia; Leukemia, other","P-507719","Wang, E","2020-02-21T00:00:00.000","2022-01-07T00:00:00.000","I","A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination with Azacitidine in Patients with Hematological Malignancies"
"Leukemia, other","P-550019","Wang, E","2021-02-03T00:00:00.000",,"III","A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-na√Øve Patients with Higher Risk Myelodysplastic Syndrome"
"Myeloid and Monocytic Leukemia; Leukemia, other","P-66718","Wang, E","2019-08-30T00:00:00.000","2021-07-14T00:00:00.000","I/II","A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia"
"Myeloid and Monocytic Leukemia","P-487719","Wang, E","2020-02-04T00:00:00.000",,"I/II","A phase Ib/2 study of IMGN632 as monotherapy or combination with venetoclax and/or azacitidine for patients with CD123+ AML"
"Myeloid and Monocytic Leukemia","P-57117","Wang, E","2018-07-11T00:00:00.000",,"I","A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123-positive Acute Myeloid Leukemia and Other CD123-
positive Hematologic Malignancies"
"Leukemia, other","P-1235721","Wang, E","2021-07-09T00:00:00.000","2021-09-03T00:00:00.000","II","A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)"
"Myeloid and Monocytic Leukemia","P-1333721","Wang, E","2021-12-09T00:00:00.000",,"III","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K; Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis"
"Myeloid and Monocytic Leukemia","P-559719","Wang, E","2020-10-16T00:00:00.000","2021-09-03T00:00:00.000","I","An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia"
"Myeloid and Monocytic Leukemia","P-84119","Wang, E","2019-09-04T00:00:00.000",,"I","A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor
KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia"
"Myeloid and Monocytic Leukemia; Leukemia, other","P-810220","Wang, E","2021-12-14T00:00:00.000",,"I","A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations"
"Multiple","P-71418","Wang, E","2019-08-15T00:00:00.000","2021-12-14T00:00:00.000","III","A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib versus Imatinib, Administered in Combination with Reduced-intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)(Ponatinib-3001)"
"Myeloid and Monocytic Leukemia; Leukemia, other","P-46617","Wang, E","2018-01-10T00:00:00.000",,"I/II","Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF)"
"Lymphoid Leukemia","P-32516","Wang, E","2017-03-30T00:00:00.000","2021-05-13T00:00:00.000","N/A","An Observational Study of Patients with Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US"
"Breast","I-571719","Witkiewicz, A","2020-07-03T00:00:00.000",,"N/A","The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Metastatic Breast Cancer Treated with CDK4/6 Inhibitors."
"Lip, Oral Cavity and Pharynx","I-67918","Wooten, K","2019-01-17T00:00:00.000",,"II","A Randomized, Multi-Center Phase 2 Trial with a Phase 1 Safety Run-in: Porfimer Sodium Mediated Interstitial Photodynamic Therapy and Standard of Care (SoC) Therapy versus SoC Therapy alone for the Treatment of Patients with Locally Advanced or Recurrent Head and Neck Cancer."
"Melanoma, Skin","I-287416","Wooten, K","2016-09-15T00:00:00.000",,"N/A","Treatment Outcomes in Cutaneous Melanoma of the Head and Neck"
"Lung","N-780320","Yau, E","2020-10-26T00:00:00.000",,"III","(A081801)Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC:ALCHEMIST Chemo-IO"
"Lung","P-55717","Yau, E","2019-08-05T00:00:00.000","2021-06-01T00:00:00.000","II","(CA-ALT-803-02-17) QUILT-3.055: A Phase 2b, Multicohort, Open-Label Study of Combination Immunotherapies in Patients who have Previously Received Treatment with PD-1/PD-L1 Immune Checkpoint Inhibitors"
"Lung","P-652220","Yau, E","2021-09-07T00:00:00.000","2021-11-05T00:00:00.000","II","CX-839-014 A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)"
"Lung","P-445719","Yau, E","2019-12-17T00:00:00.000","2021-05-05T00:00:00.000","II","A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)"
"Lung","P-487819","Yau, E","2020-04-06T00:00:00.000",,"I/II","A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation"
"Bladder","I-661820","Yeary, K","2020-08-25T00:00:00.000",,"I","POW-R Health: Power to Redefine your Health (Internal Title: A Pragmatic Dietary Intervention to Improve Bladder Cancer Survivorship)"
,"I-684220","Yeary, K","2020-08-25T00:00:00.000",,"N/A","Weight loss interventions for black adults of faith"
"Lung","I-72818","Yendamuri, S","2019-01-22T00:00:00.000",,"N/A","Preoperative Respiratory Muscle Training to Prevent Postoperative Pulmonary Complications in Patients Undergoing Resection for Lung Cancer"
,"I-62118","Yendamuri, S","2021-09-17T00:00:00.000",,"I","Light Dosimetry for Intraoperative Photodynamic Therapy (IO-PDT) with Porfimer 
Sodium (Photofrin¬Æ) in Patients with Malignant Mesothelioma, Non-Small Cell Lung 
Cancer (NSCLC), or Other Malignancies with Pleural Disease - Phase I Study"
"Lung","I-767720","Yendamuri, S","2021-11-05T00:00:00.000",,"I","Utilizing Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC) with Pleural Disease - Phase I Study"
"Lung","P-825720","Yendamuri, S","2021-10-19T00:00:00.000",,"II","CHIO3 Trial: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer"
"Multiple Sites","I-66018","Yendamuri, S","2019-02-07T00:00:00.000",,"N/A","Endoscopy Sample Collection Protocol"
"Soft Tissue","P-39716","Zsiros, E","2017-10-04T00:00:00.000","2021-04-30T00:00:00.000","I/II","A Phase 1/2 dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies (LUD2015-008"
"Ovary","I-287616","Zsiros, E","2019-01-24T00:00:00.000","2021-05-07T00:00:00.000","I","A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) after a Myeloablative Conditioning Regimen, with Administration of IL-2 in Patients with Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer"
"Other Female Genital; Ovary","I-248613","Zsiros, E","2014-08-01T00:00:00.000","2020-01-02T00:00:00.000","I/II","A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given with Adjuvant Poly-ICLC in Combination with INCB024360 for Patients in Remission with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen"
"Other Female Genital; Ovary","I-288216","Zsiros, E","2017-06-29T00:00:00.000","2021-04-28T00:00:00.000","I/II","A Phase I/II Evaluation of Olaparib in combination with Durvalumab and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients who Carry a Germline BRCA1 or BRCA2 Mutation"
"Other Female Genital; Ovary","I-43717","Zsiros, E","2017-11-06T00:00:00.000","2021-05-05T00:00:00.000","Early Phase I","A Pilot Study of Feasibility of Performing Intravital Microscopy in Patients with Ovarian, Primary Peritoneal or Fallopian Tube Cancer"
"Cervix Uteri","P-38016","Zsiros, E","2017-07-07T00:00:00.000",,"II","A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma"
"Corpus Uteri; Ovary","I-37616","Zsiros, E","2016-12-12T00:00:00.000",,"N/A","Life On The Go 1: Evaluating the Effect of Baseline Physical Activity of Patients with Endometrial and Ovarian Cancer using State of the Art Activity Tracking Device"
"Unknown Sites","I-56117","Zsiros, E","2018-06-13T00:00:00.000",,"N/A","The GYN Molecular Information Registry"
"Other Female Genital; Ovary","I-61818","Zsiros, E","2018-03-22T00:00:00.000","2021-02-14T00:00:00.000","N/A","Opioid Use in Post-operative Gynecologic Oncology Patients"
"Unknown Sites","I-65018","Zsiros, E","2018-06-06T00:00:00.000","2021-05-21T00:00:00.000","N/A","Evaluation of Burnout and Wellness Among Gynecologic Oncology Fellows Nationwide"
"Multiple Sites","I-215512","Zsiros, E","2014-02-14T00:00:00.000",,"N/A","Analysis of Tumor Antigens, Immunity, and Genetic Changes in Gynecological Cancer Patients"
